Literature DB >> 34080912

Role of sex hormones in lung cancer.

Nathalie Fuentes1, Miguel Silva Rodriguez2, Patricia Silveyra2.   

Abstract

Lung cancer represents the world's leading cause of cancer deaths. Sex differences in the incidence and mortality rates for various types of lung cancers have been identified, but the biological and endocrine mechanisms implicated in these disparities have not yet been determined. While some cancers such as lung adenocarcinoma are more commonly found among women than men, others like squamous cell carcinoma display the opposite pattern or show no sex differences. Associations of tobacco product use rates, susceptibility to carcinogens, occupational exposures, and indoor and outdoor air pollution have also been linked to differential rates of lung cancer occurrence and mortality between sexes. While roles for sex hormones in other types of cancers affecting women or men have been identified and described, little is known about the influence of sex hormones in lung cancer. One potential mechanism identified to date is the synergism between estrogen and some tobacco compounds, and oncogene mutations, in inducing the expression of metabolic enzymes, leading to enhanced formation of reactive oxygen species and DNA adducts, and subsequent lung carcinogenesis. In this review, we present the literature available regarding sex differences in cancer rates, associations of male and female sex hormones with lung cancer, the influence of exogenous hormone therapy in women, and potential mechanisms mediated by male and female sex hormone receptors in lung carcinogenesis. The influence of biological sex on lung disease has recently been established, thus new research incorporating this variable will shed light on the mechanisms behind the observed disparities in lung cancer rates, and potentially lead to the development of new therapeutics to treat this devastating disease.

Entities:  

Keywords:  Lung; cancer; carcinogenesis; estrogen receptors; sex differences; sex hormones

Mesh:

Substances:

Year:  2021        PMID: 34080912      PMCID: PMC8524770          DOI: 10.1177/15353702211019697

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  154 in total

1.  The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.

Authors:  Nadiyah Kazmi; Diana C Márquez-Garbán; Lilia Aivazyan; Nalo Hamilton; Edward B Garon; Lee Goodglick; Richard J Pietras
Journal:  Lung Cancer Manag       Date:  2012-12

Review 2.  ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2017-04-30       Impact factor: 7.658

3.  Hormone replacement therapy and lung cancer risk in Chinese.

Authors:  Kuan-Yu Chen; Chin-Fu Hsiao; Gee-Chen Chang; Yin-Huang Tsai; Wu-Chou Su; Reury-Perng Perng; Ming-Shyan Huang; Chao A Hsiung; Chien-Jen Chen; Pan-Chyr Yang
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

4.  Expression of estrogen receptors alpha and beta in human lung tissue and cell lines.

Authors:  Steen Mollerup; Kjersti Jørgensen; Gisle Berge; Aage Haugen
Journal:  Lung Cancer       Date:  2002-08       Impact factor: 5.705

5.  Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.

Authors:  Rowan T Chlebowski; Ann G Schwartz; Heather Wakelee; Garnet L Anderson; Marcia L Stefanick; JoAnn E Manson; Rebecca J Rodabough; Jason W Chien; Jean Wactawski-Wende; Margery Gass; Jane Morley Kotchen; Karen C Johnson; Mary Jo O'Sullivan; Judith K Ockene; Chu Chen; F Allan Hubbell
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

Review 6.  Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor.

Authors:  Ellis R Levin
Journal:  Mol Endocrinol       Date:  2002-12-12

Review 7.  The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism.

Authors:  Sigal Ben-Zaken Cohen; Peter D Paré; S F Paul Man; Don D Sin
Journal:  Am J Respir Crit Care Med       Date:  2007-04-05       Impact factor: 21.405

8.  Tobacco smoke induces CYP1B1 in the aerodigestive tract.

Authors:  Jeffrey L Port; Kentaro Yamaguchi; Baoheng Du; Mariana De Lorenzo; Mindy Chang; Paul M Heerdt; Levy Kopelovich; Craig B Marcus; Nasser K Altorki; Kotha Subbaramaiah; Andrew J Dannenberg
Journal:  Carcinogenesis       Date:  2004-08-05       Impact factor: 4.944

9.  miR-224-5p-enriched exosomes promote tumorigenesis by directly targeting androgen receptor in non-small cell lung cancer.

Authors:  Jinbao Zhou; Hongshu Wang; Qiangling Sun; Xiaomin Liu; Zong Wu; Xianyi Wang; Wentao Fang; Zhongliang Ma
Journal:  Mol Ther Nucleic Acids       Date:  2021-02-03       Impact factor: 8.886

10.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

View more
  2 in total

1.  Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER-Medicare Database Analysis.

Authors:  Bassel Nazha; Chao Zhang; Zhengjia Chen; Camille Ragin; Taofeek K Owonikoko
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

2.  The spatiotemporal dynamics of lung cancer: 30-year trends of epidemiology across 204 countries and territories.

Authors:  Xiang Chen; Shaoyan Mo; Bin Yi
Journal:  BMC Public Health       Date:  2022-05-16       Impact factor: 4.135

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.